Evidence map›Paper›PMID 36147476›Full record

ArticleInternational journal of biological sciences2022

Fangteng Liu, Nassim Bouznad, Markus Kaller, Xiaolong Shi, Janine König, Stephanie Jaeckel, Heiko Hermeking

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fangteng LiuExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Nassim BouznadExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Markus KallerExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Xiaolong ShiExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Janine KönigExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Stephanie JaeckelExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Heiko HermekingExperimental and Molecular Pathology, Institute of Pathology, Ludwig-Maximilians-University München, Germany.
Ludwig-Maximilians-Universität München · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CSF1 receptor (CSF1R) encoding mRNA represents a direct target of miR-34a. However, the

Indexed as

AdenomaMicroRNAsReceptors, Granulocyte-Macrophage Colony-Stimulating FactorAnimalsCell Line, TumorCell Transformation, NeoplasticFluorouracilGene Expression Regulation, NeoplasticMiceNetrin-1Receptor Protein-Tyrosine KinasesRNA, MessengerTumor Suppressor Protein p53Csf1r protein, mouseFluorouracilMicroRNAsMIRN34a microRNA, mouseNetrin-1Receptor Protein-Tyrosine KinasesReceptors, Granulocyte-Macrophage Colony-Stimulating FactorRNA, MessengerTumor Suppressor Protein p53APCcolorectal cancerCsf1rCSF1Rintestinal adenomasmiR-34aMiR34aNtn1p53Tagln

Identifiers

PMID36147476
PMCPMC9461672
OpenAlexW4295222536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.